|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Le Rhun E, Preusser M, Roth P, Reardon DA,
van den Bent M, Wen P, Reifenberger G and Weller M: Molecular
targeted therapy of glioblastoma. Cancer Treat Rev. 80:1018962019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bernstock JD, Mooney JH, Ilyas A, Chagoya
G, Estevez-Ordonez D, Ibrahim A and Nakano I: Molecular and
cellular intratumoral heterogeneity in primary glioblastoma:
Clinical and translational implications. J Neurosurg. 23:1–9.
2019.
|
|
4
|
Aldape K, Zadeh G, Mansouri S,
Reifenberger G and von Deimling A: Glioblastoma: Pathology,
molecular mechanisms and markers. Acta Neuropathol. 129:829–848.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Delgado-Martín B and Medina MÁ: Advances
in the knowledge of the molecular biology of glioblastoma and its
impact in patient diagnosis, stratification, and treatment. Adv
Sci. 7:19029712020. View Article : Google Scholar
|
|
6
|
Hara A, Kanayama T, Noguchi K, Niwa A,
Miyai M, Kawaguchi M, Ishida K, Hatano Y, Niwa M and Tomita H:
Treatment strategies based on histological targets against invasive
and resistant glioblastoma. J Oncol. 2019:29647832019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Garton ALA, Kinslow CJ, Rae AI, Mehta A,
Pannullo SC, Magge RS, Ramakrishna R, McKhann GM, Sisti MB, Bruce
JN, et al: Extent of resection, molecular signature, and survival
in 1p19q-codeleted gliomas. J Neurosurg. 8:1–11. 2020. View Article : Google Scholar
|
|
8
|
Zhang X, Zhang W, Mao XG, Cao WD, Zhen HN
and Hu SJ: Malignant intracranial high grade glioma and current
treatment strategy. Curr Cancer Drug Targets. 19:101–108. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li C, Jing H, Ma G and Liang P: Allicin
induces apoptosis through activation of both intrinsic and
extrinsic pathways in glioma cells. Mol Med Rep. 17:5976–5981.
2018.PubMed/NCBI
|
|
10
|
Tamura R, Tanaka T, Miyake K, Yoshida K
and Sasaki H: Bevacizumab for malignant gliomas: Current
indications, mechanisms of action and resistance, and markers of
response. Brain Tumor Pathol. 34:62–77. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sanchez Calle A, Kawamura Y, Yamamoto Y,
Takeshita F and Ochiya T: Emerging roles of long non-coding RNA in
cancer. Cancer Sci. 109:2093–2100. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wei JW, Huang K, Yang C and Kang CS:
Non-coding RNAs as regulators in epigenetics. Oncol Rep. 37:3–9.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Derrien T, Johnson R, Bussotti G, Tanzer
A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG,
et al: The GENCODE v7 catalog of human long noncoding RNAs:
Analysis of their gene structure, evolution, and expression. Genome
Res. 22:1775–1789. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gaballa JM, Braga Neto MB, Ramos GP,
Bamidele AO, Gonzalez MM, Sagstetter MR, Sarmento OF and Faubion WA
Jr: The role of histone methyltransferases and long non-coding RNAs
in the regulation of T cell fate decisions. Front Immunol.
9:29552018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Spizzo R, Almeida MI, Colombatti A and
Calin GA: Long non-coding RNAs and cancer: A new frontier of
translational research. Oncogene. 31:4577–4587. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li CY, Zhang WW, Xiang JL, Wang XH, Wang
JL and Li J: Integrated analysis highlights multiple long
non-coding RNAs and their potential roles in the progression of
human esophageal squamous cell carcinoma. Oncol Rep. 42:2583–2599.
2019.PubMed/NCBI
|
|
17
|
DeOcesano-Pereira C, Machado RAC,
Chudzinski-Tavassi AM and Sogayar MC: Emerging roles and potential
applications of non-coding RNAs in glioblastoma. Int J Mol Sci.
21:E26112020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Connerty P, Lock RB and de Bock CE: Long
non-coding RNAs: Major regulators of cell stress in cancer. Front
Oncol. 10:2852020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Renganathan A and Felley-Bosco E: Long
noncoding RNAs in cancer and therapeutic potential. Adv Exp Med
Biol. 1008:199–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang G, Lu X and Yuan L: lncRNA: A link
between RNA and cancer. Biochim Biophys Acta. 1839:1097–1109. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu C, Li X, Hao Y, Wang F, Cheng Z, Geng
H and Geng D: STAT1-induced upregulation of lncRNA KTN1-AS1
predicts poor prognosis and facilitate non-small cell lung cancer
progression via miR-23b/DEPDC1 axis. Aging (Albany NY).
12:8680–8701. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang L, Wang L, Wang Y, Chen T, Liu R,
Yang W, Liu Q and Tu K: lncRNA KTN1-AS1 promotes tumor growth of
hepatocellular carcinoma by targeting miR-23c/ERBB2IP axis. Biomed
Pharmacother. 109:1140–1147. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jiang Y, Wu K, Cao W, Xu Q, Wang X, Qin X,
Wang X, Li Y, Zhang J and Chen W: Long noncoding RNA KTN1-AS1
promotes head and neck squamous cell carcinoma cell
epithelial-mesenchymal transition by targeting miR-153-3p.
Epigenomics. 12:487–505. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cao W, Liu JN, Liu Z, Wang X, Han ZG, Ji
T, Chen WT and Zou X: A three-lncRNA signature derived from the
Atlas of ncRNA in cancer (TANRIC) database predicts the survival of
patients with head and neck squamous cell carcinoma. Oral Oncol.
65:94–101. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
General Assembly of the World Medical
Association, . World medical association declaration of Helsinki:
Ethical principles for medical research involving human subjects. J
Am Coll Dent. 81:14–18. 2014.PubMed/NCBI
|
|
26
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res. 41:D991–D995. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kong B, Yang T, Chen L, Kuang YQ, Gu JW,
Xia X, Cheng L and Zhang JH: Protein-protein interaction network
analysis and gene set enrichment analysis in epilepsy patients with
brain cancer. J Clin Neurosci. 21:316–319. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hawkins SF and Guest PC: Multiplex
analyses using real-time quantitative PCR. Methods Mol Biol.
1546:125–133. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen X, Robinson DG and Storey JD: The
functional false discovery rate with applications to genomics.
Biostatistics. 28:kxz0102019. View Article : Google Scholar
|
|
30
|
Zhang JF, Wang P, Yan YJ, Li Y, Guan MW,
Yu JJ and Wang XD: IL-33 enhances glioma cell migration and
invasion by upregulation of MMP2 and MMP9 via the ST2-NF-κB
pathway. Oncol Rep. 38:2033–2042. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yao Z, Zhang Y, Xu D, Zhou X, Peng P, Pan
Z, Xiao N, Yao J and Li Z: Research progress on long non-coding RNA
and radiotherapy. Med Sci Monit. 25:5757–5770. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jalali S, Bhartiya D, Lalwani MK,
Sivasubbu S and Scaria V: Systematic transcriptome wide analysis of
lncRNA-miRNA interactions. PLoS One. 8:e538232013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gutschner T, Hämmerle M, Eissmann M, Hsu
J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al:
The noncoding RNA MALAT1 is a critical regulator of the metastasis
phenotype of lung cancer cells. Cancer Res. 73:1180–1189. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li Y, Wang K, Wei Y, Yao Q, Zhang Q, Qu H
and Zhu G: lncRNA-MIAT regulates cell biological behaviors in
gastric cancer through a mechanism involving the miR-29a-3p/HDAC4
axis. Oncol Rep. 6:3465–3472. 2017.
|
|
35
|
Li C, Zheng H, Hou W, Bao H, Xiong J, Che
W, Gu Y, Sun H and Liang P: Long non-coding RNA linc00645 promotes
TGF-β-induced epithelial-mesenchymal transition by regulating
miR-205-3p-ZEB1 axis in glioma. Cell Death Dis. 10:7172019.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu M, Wang G, Tian W, Deng Y and Xu Y:
miRNA-based therapeutics for lung cancer. Curr Pharm Des.
23:5989–5996. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shin VY and Chu KM: miRNA as potential
biomarkers and therapeutic targets for gastric cancer. World J
Gastroenterol. 20:10432–10439. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fridrichova I and Zmetakova I: MicroRNAs
contribute to breast cancer invasiveness. Cells. 8:13612019.
View Article : Google Scholar
|
|
40
|
Deng JH, Deng Q, Kuo CH, Delaney SW and
Ying SY: miRNA targets of prostate cancer. Methods Mol Biol.
936:357–369. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang J, Liu H and Li M: Downregulation of
miR-505 promotes cell proliferation, migration and invasion, and
predicts poor prognosis in breast cancer. Oncol Lett. 18:247–254.
2019.PubMed/NCBI
|
|
42
|
Shi H, Yang H, Xu S, Zhao Y and Liu J:
miR-505 functions as a tumor suppressor in glioma by targeting
insulin like growth factor 1 receptor expression. Int J Clin Exp
Pathol. 11:4405–4413. 2018.PubMed/NCBI
|
